vs
Side-by-side financial comparison of Golden Matrix Group, Inc. (GMGI) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $49.6M, roughly 1.2× Golden Matrix Group, Inc.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -92.6% vs -179.0%, a 86.4% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -15.8%). Over the past eight quarters, Golden Matrix Group, Inc.'s revenue compounded faster (104.6% CAGR vs 43.8%).
Golden Matrix Group Inc. is a global gaming tech firm that develops and licenses proprietary online gaming platforms, social casino products and interactive solutions. It serves B2B gaming operator clients across North America, Europe and Asia-Pacific, plus runs direct-to-consumer casual gaming properties.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
GMGI vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $49.6M | $60.1M |
| Net Profit | $-88.7M | $-55.6M |
| Gross Margin | 57.5% | 88.1% |
| Operating Margin | -188.3% | -87.1% |
| Net Margin | -179.0% | -92.6% |
| Revenue YoY | -15.8% | 83.8% |
| Net Profit YoY | -4880.1% | — |
| EPS (diluted) | $-7.73 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $49.6M | $57.3M | ||
| Q3 25 | $47.3M | $51.3M | ||
| Q2 25 | $43.2M | $48.5M | ||
| Q1 25 | $42.7M | $32.7M | ||
| Q4 24 | $58.9M | $41.8M | ||
| Q3 24 | $41.0M | $33.3M | ||
| Q2 24 | $39.4M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $-88.7M | $-47.5M | ||
| Q3 25 | $566.0K | $-52.9M | ||
| Q2 25 | $-3.6M | $-46.6M | ||
| Q1 25 | $-231.6K | $-49.5M | ||
| Q4 24 | $1.9M | $-43.3M | ||
| Q3 24 | $-3.4M | $-43.6M | ||
| Q2 24 | $64.9K | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | 57.5% | 91.6% | ||
| Q3 25 | 55.8% | 89.3% | ||
| Q2 25 | 56.4% | 88.6% | ||
| Q1 25 | 56.6% | 88.8% | ||
| Q4 24 | 69.8% | 90.9% | ||
| Q3 24 | 54.7% | 88.5% | ||
| Q2 24 | 55.0% | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | -188.3% | -82.2% | ||
| Q3 25 | -0.8% | -102.6% | ||
| Q2 25 | -5.3% | -93.4% | ||
| Q1 25 | -0.2% | -143.7% | ||
| Q4 24 | 5.6% | -98.6% | ||
| Q3 24 | -2.4% | -132.0% | ||
| Q2 24 | 0.3% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | -179.0% | -83.0% | ||
| Q3 25 | 1.2% | -103.1% | ||
| Q2 25 | -8.3% | -96.1% | ||
| Q1 25 | -0.5% | -151.4% | ||
| Q4 24 | 3.2% | -103.6% | ||
| Q3 24 | -8.3% | -131.2% | ||
| Q2 24 | 0.2% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $-7.73 | $-0.73 | ||
| Q3 25 | $0.00 | $-0.82 | ||
| Q2 25 | $-0.03 | $-0.75 | ||
| Q1 25 | $0.00 | $-0.81 | ||
| Q4 24 | $-0.13 | $-0.71 | ||
| Q3 24 | $-0.03 | $-0.73 | ||
| Q2 24 | $0.00 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $46.5M | $122.9M |
| Total Assets | $118.1M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $46.5M | $139.1M | ||
| Q3 25 | $123.5M | $148.8M | ||
| Q2 25 | $121.3M | $-11.9M | ||
| Q1 25 | $108.5M | $18.9M | ||
| Q4 24 | $105.1M | $21.7M | ||
| Q3 24 | $94.3M | $11.2M | ||
| Q2 24 | $90.4M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $118.1M | $480.2M | ||
| Q3 25 | $209.8M | $506.9M | ||
| Q2 25 | $210.3M | $372.7M | ||
| Q1 25 | $214.0M | $386.7M | ||
| Q4 24 | $213.7M | $392.3M | ||
| Q3 24 | $213.5M | $363.6M | ||
| Q2 24 | $191.5M | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | — |
| Free Cash FlowOCF − Capex | $6.4M | — |
| FCF MarginFCF / Revenue | 13.0% | — |
| Capex IntensityCapex / Revenue | 3.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $19.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $-25.4M | ||
| Q3 25 | $7.0M | $-26.6M | ||
| Q2 25 | $2.4M | $-23.3M | ||
| Q1 25 | $7.7M | $-40.4M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $4.8M | $-25.2M | ||
| Q2 24 | — | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $6.4M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $-89.4K | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.0% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | -0.2% | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 5.7% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 12.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GMGI
| R Kings And CFAC | $43.8M | 88% |
| Other | $5.8M | 12% |
RYTM
Segment breakdown not available.
